Article
Neurosciences
Agata Korlatowicz, Paulina Pabian, Joanna Solich, Magdalena Kolasa, Katarzyna Latocha, Marta Dziedzicka-Wasylewska, Agata Faron-Gorecka
Summary: This study focused on the selection of miRNAs that differentiate the Wistar Kyoto rat strain from the Wistar Han rat strain in the lateral habenula and medial habenula. The results showed significant miRNA expression differences in these two brain regions, which correlated with alterations in the expression of target transcripts. Notably, two genes, Slc12a5 and Htr7, were found to be altered in both regions and may serve as potential targets for the treatment of TRD.
MOLECULAR NEUROBIOLOGY
(2023)
Article
Oncology
C. Barcelo, P. Siso, I. de la Rosa, C. Megino-Luque, R. Navaridas, O. Maiques, I. Urdanibia, N. Eritja, X. Soria, M. Potrony, N. Calbet-Llopart, S. Puig, X. Matias-Guiu, R. M. Marti, A. Macia
Summary: Secreted M-CSF induces a BRAFi-resistant phenotype and signifies a worse prognosis in metastatic BRAF(V600E) melanoma patients. These findings identify secreted M-CSF as a promising therapeutic target for treating BRAFi-resistant melanomas.
BRITISH JOURNAL OF CANCER
(2022)
Article
Biophysics
Wanming Li, Chia-Chun Wu, Shuo Wang, Linlin Zhou, Lei Qiao, Wei Ba, Furong Liu, Linan Zhan, Hang Chen, Jau-Song Yu, Jin Fang
Summary: In this study, a new metastatic biomarker W3 and its target molecule EphA2 were discovered. A cell-SELEX-based biomarker discovery strategy was proposed, which allows for a faster and more targeted discovery of biomarkers.
BIOSENSORS & BIOELECTRONICS
(2022)
Review
Oncology
Kah Keng Wong
Summary: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, with DNMT1 playing a crucial role in promoting tumorigenesis through multiple mechanisms. DNMT1 inhibitors show promise in targeting TNBC cells and sensitizing patients to immune checkpoint blockade therapy. This highlights the potential of DNMT1 as a therapeutic target for TNBC, aiming to disrupt its metastatic and aggressive phenotypes.
SEMINARS IN CANCER BIOLOGY
(2021)
Review
Medicine, Research & Experimental
Feyza Gul Ozbay Kurt, Samantha Lasser, Ihor Arkhypov, Jochen Utikal, Viktor Umansky
Summary: Despite the success of immune checkpoint inhibitors in melanoma treatment, resistance to them remains a challenge. Myeloid-derived suppressor cells play a crucial role in ICI resistance and creating an immunosuppressive tumor microenvironment. Targeting MDSCs is considered a promising strategy to improve melanoma immunotherapy, and this review discusses the mechanism, studies, and potential strategies for inhibiting MDSC functions.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Article
Biochemistry & Molecular Biology
Claudio Tabolacci, Deborah Giordano, Stefania Rossi, Martina Cordella, Daniela D'Arcangelo, Federica Moschella, Stefania D'Atri, Mauro Biffoni, Angelo Facchiano, Francesco Facchiano
Summary: The study identified DLD as a potential target for overcoming vemurafenib resistance in melanoma cells, through proteomic and structural investigations on resistant sublines.
Review
Oncology
Peipei Li, Fangchao Li, Yanfei Zhang, Xiaoyang Yu, Jingjing Li
Summary: Tumor-infiltrating T cells play a crucial role in modulating the tumor microenvironment and are potential targets for cancer immunotherapy. However, these T lymphocytes show significant heterogeneity and dynamics across different tumor microenvironments and cancer types, which can influence cancer growth, metastasis, relapse, and response to drugs. In addition to subpopulation composition, T cell metabolic states also contribute to their heterogeneity. This review discusses the reprogramming of T cell metabolism triggered by the tumor microenvironment and the potential use of metabolic targeting drugs. The metabolic pathway addictions of tumor-infiltrating T cells in different cancer types are also addressed.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Cell Biology
Martina Quartieri, Anggraeini Puspitasari, Tamara Vitacchio, Marco Durante, Walter Tinganelli
Summary: This study investigates the interplay between acute and chronic hypoxia and radiation exposure in selecting and characterizing cells with a Circulating Cancer Stem Cell (CCSC)-like phenotype. The results demonstrate that the combination of radiation and acute hypoxia enhances stemness, while chronic hypoxia imparts a cancer stem-like phenotype in cells.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Review
Pharmacology & Pharmacy
Daniel J. Smit, Klaus Pantel, Manfred Juecker
Summary: CTCs play a crucial role in cancer metastasis and their analysis in liquid biopsies can be valuable for prognosis prediction and real-time therapy monitoring. Research on CTCs may lead to new treatment strategies for preventing metastasis or maintaining stable diseases. Studies on inhibitors targeting CTCs have shown promising results, suggesting CTCs may be useful for personalized drug susceptibility testing.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Oncology
Esteban Enrique Elias, Valeria Judith Sarapura Martinez, Mikele Amondarain, Ana Colado, Gregorio Cordini, Raimundo Fernando Bezares, Horacio Fernandez Grecco, Maria del Rosario Custidiano, Julio Cesar Sanchez avalos, Gonzalo Garate, Miguel A. Pavlovsky, Mercedes Borge, Mirta Giordano, Romina Gamberale
Summary: Venetoclax treatment has shown efficacy and safety in CLL patients, but resistance remains a challenge. This study found that venetoclax-resistant CLL cells displayed an aggressive phenotype with increased expression of anti-apoptotic proteins like BCL-XL and MCL-1, and sustained resistance to further treatment. Inhibitors of SYK and PI3Kδ were able to reduce T cell activation, impair aggressive leukemia cell generation, and restore sensitivity to venetoclax.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Review
Biochemistry & Molecular Biology
Elvira Crescenzi, Antonio Leonardi, Francesco Pacifico
Summary: The review focuses on the different roles of NGAL in the tumor microenvironment and in cancer senescence-associated secretory phenotype (SASP), highlighting the most crucial functions that could be eventually targetable in cancer therapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Pharmacology & Pharmacy
Yi Xiao, Dihua Yu
Summary: This article summarizes the current progress in targeting the tumor microenvironment in both drug development and clinical trials, emphasizing the challenges in intervening in the tumor microenvironment and discussing strategies to maximize therapeutic benefits. New technologies and approaches to better understand the tumor microenvironment are explored in this context.
PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Oncology
Muhammad Aizaz, Aakif Khan, Faisal Khan, Maria Khan, Ebraheem Abdu Musad Saleh, Maryum Nisar, Natalia Baran
Summary: Macrophages play an important role in cancer progression and interact with tumor cells. Targeting macrophage-tumor cell cross-talk through therapeutic strategies can reverse immunosuppression and tumor-protective environment to enhance antitumor response. However, tumor hypoxia and acidosis pose barriers to effective cancer therapy.
FRONTIERS IN ONCOLOGY
(2023)
Review
Medicine, Research & Experimental
Yemil Atisha-Fregoso, Bahtiyar Toz, Betty Diamond
Summary: B cells play a key role in the development of SLE, producing pathogenic antibodies that enhance inflammation and damage tissues and cells. While multiple therapies targeting B cells have been successful in mouse models, only belimumab has been approved for SLE treatment in patients. Integrating previous clinical trial experience with new research on B cell mechanisms in specific patient groups is crucial for developing effective treatment strategies, particularly focusing on B cell differentiation into plasma cells.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Review
Medicine, Research & Experimental
Yihui Yang, Liwen Ren, Wan Li, Yizhi Zhang, Sen Zhang, Binbin Ge, Hong Yang, Guanhua Du, Bo Tang, Hongquan Wang, Jinhua Wang
Summary: GABA is a common inhibitory neurotransmitter in the central nervous system of vertebrates, and recent studies have shown its involvement in tumor development and immune regulation. This review summarizes the role of GABAergic signaling in tumor proliferation, metastasis, progression, stemness, and the tumor microenvironment, as well as the underlying molecular mechanisms. The therapeutic advances in targeting GABA receptors for cancer treatment, particularly immunotherapy, are also discussed.
BIOMEDICINE & PHARMACOTHERAPY
(2023)